Business
Viridian Therapeutics to Present at Three Upcoming Investor Conferences
BOULDER, Colo., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"BOULDER, Colo., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the following upcoming investor conferences: Event:SVB Leerink 10TH Annual Global Healthcare Conference 2021 (Virtual)Date: Wednesday, February 24THPresentation Time:1:00 p.m. EST Event: Cowen 41ST Annual Health Care Conference 2021 (Virtual)Date:Wednesday, March 3RDPresentation Time:11:40 a.m. EST Event: Oppenheimer 31ST Annual Healthcare Conference 2021 (Virtual)Date:Tuesday, March 16THPresentation Time: 11:20 a.m. EST Webcast information for these events will be accessible on the Events page under the Investors section of the Viridian Therapeutics website at www.viridiantherapeutics.com. A replay of the presentations will be archived on the website and available for approximately 90 days following each live event. About Viridian Therapeutics Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado, with research and development operations in Waltham, Massachusetts. Learn more about Viridian and our programs at www.viridiantherapeutics.com. Follow us on Twitter @ViridianThera and on LinkedIn. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"will,\" or \"would\" or other similar terms or expressions that concern Viridian’s expectation, strategy, plans or intentions. Forward looking statements include, without limitation, statements regarding the Company’s future research and clinical development plans and the potential commencement of the Company’s Phase 2 clinical trial and the timing for any of these ...